Kimberley Clark
South Australian Immunogenomics Cancer Institute
Faculty of Health and Medical Sciences
Eligible to supervise Masters and PhD - email supervisor to discuss availability.
Dr. Kimberley Clark is a Research Fellow in the South Australian Immunogenomics Cancer Institute (SAiGENCI) at the University of Adelaide. In 2020, Dr. Clark was awarded her PhD from the University of Adelaide, South Australia. Her doctoral research was carried out under the supervision of Prof. Andrew Zannettino in the Myeloma Research Laboratory, SAHMRI, and focused on the role of the bone marrow tumour microenvironment in myeloma tumour growth and spread. Following her PhD studies, Dr. Clark continued her postdoctoral studies at Monash University, Victoria, Australia in a combined research program with Prof. Roger Daly and A/Prof. Renea Taylor. At Monash University, Dr. Clark's research interests involved investigating signaling networks between cancer-associated fibroblasts and tumour cells in prostate cancer. This research utilized novel proteomic techniques and pre-clinical models of cancer. In 2023, Dr. Clark returned to Adelaide to join the Sweeney Laboratory, SAiGENCI.
Student Project Opportunities
Options for prospective Honours, Masters and PhD students
Identification and validation of novel MYBL2 inhibitors for prostate cancer: MYBL2, a MYB family transcription factor, is a physiological regulator of cell cycle progression, cell survival and cell differentiation. MYBL2 is commonly amplified in aggressive castrate resistant disease. The aim of this project is to determine the mechanisms of MYBL2 upregulation in prostate cancer and its role in different disease stages. Secondly, this project aims to investigate and validate candidate compounds from a virtual screening platform as novel MYBL2 inhibitors that can be used in treatment of aggressive PCa.
Investigating a role for NF-KB inhibition in overcoming therapeutic resistance to EGFR TKIs in lung cancer: Lung cancer is the leading cause of cancer deaths worldwide. Mutations in the epidermal growth factor receptor (EGFR) gene are one of the most commonly observed mutations in patients with non-small cell lung cancer (NSCLC). Multiple generations of EGFR tyrosine kinase inhibitors (TKIs) have provided significant benefit to clinical outcomes of patients with NSCLC, however resistance and/or disease recurrence almost always occurs. NF-KB signalling is known to be upregulated in EGFR TKI-resistant NSCLC, and preclinical studies have demonstrated that NF-KB inhibition may provide an additional survival benefit when combined with EGFR TKIs. The aim of this project is to identify the cellular mechanisms by which NF-KB upregulation occurs in EGFR-TKI resistance in NSCLC, and to investigate whether NFKB can be targeted in pre-clinical animal models of NSCLC to overcome this.
-
Education
Date Institution name Country Title University of Adelaide, Adelaide Australia Bachelor of Health Science- Honours Flinders University Australia Bachelor of Medical Science -
Postgraduate Training
Date Title Institution Country 2015 - 2020 Doctor of Philosophy University of Adelaide Australia -
Research Interests
-
Journals
Year Citation 2023 Wu, Y., Clark, K. C., Niranjan, B., Chüeh, A. C., Horvath, L. G., Taylor, R. A., & Daly, R. J. (2023). Integrative characterisation of secreted factors involved in intercellular communication between prostate epithelial or cancer cells and fibroblasts. Molecular Oncology, 17(3), 469-486.
WoS1 Europe PMC42023 Yang, X., Cruz, M. I., Nguyen, E. V., Huang, C., Schittenhelm, R. B., Luu, J., . . . Daly, R. J. (2023). The pseudokinase NRBP1 activates Rac1/Cdc42 via P-Rex1 to drive oncogenic signalling in triple-negative breast cancer. Oncogene, 42(11), 833-847.
Scopus2 WoS1 Europe PMC22023 Clark, K. C., Nguyen, E. V., Niranjan, B., Wu, Y., Lim Kam Sian, T. C. C., Horvath, L. G., . . . Daly, R. J. (2023). Cell-Type-Specific Signalling Networks Impacted by Prostate Epithelial-Stromal Intercellular Communication. Cancers, 15(3), 699.
Scopus1 WoS1 Europe PMC12022 Clark, K. C., Wu, Y., Taylor, R. A., & Daly, R. J. (2022). Novel Therapeutic Targets and Biomarkers Associated with Prostate Cancer-Associated Fibroblasts (CAFs).. Critical reviews in oncogenesis, 27(1), 1-24.
Europe PMC12022 Wu, Y., Clark, K. C., Nguyen, E. V., Niranjan, B., Horvath, L. G., Taylor, R. A., & Daly, R. J. (2022). Proteomic characterisation of prostate cancer intercellular communication reveals cell type-selective signalling and TMSB4X-dependent fibroblast reprogramming. Cellular Oncology, 45(6), 1311-1328.
WoS1 Europe PMC22020 Friend, N., Noll, J. E., Opperman, K. S., Clark, K. C., Mrozik, K. M., Vandyke, K., . . . Zannettino, A. C. W. (2020). GLIPR1 expression is reduced in multiple myeloma but is not a tumour suppressor in mice.. PLoS One, 15(1), e0228408.
WoS2 Europe PMC12020 Clark, K. C., Hewett, D. R., Panagopoulos, V., Plakhova, N., Opperman, K. S., Bradey, A. L., . . . Zannettino, A. C. W. (2020). Targeted disruption of bone marrow stromal cell-derived Gremlin1 limits multiple myeloma disease progression in vivo. Cancers, 12(8), 2149-1-2149-20.
Scopus6 WoS5 Europe PMC32019 Opperman, K. S., Vandyke, K., Clark, K. C., Coulter, E. A., Hewett, D. R., Mrozik, K. M., . . . Zannettino, A. C. (2019). Clodronate-liposome mediated macrophage depletion abrogates multiple myeloma tumor establishment in vivo. Neoplasia, 21(8), 777-787.
Scopus51 WoS44 Europe PMC37 -
Conference Items
Year Citation 2019 Clark, K., Hewett, D., Panagopoulos, V., Davies, G., & Zannettino, A. (2019). Targeting stromal-derived Gremlin1 to control Multiple Myeloma disease development. Poster session presented at the meeting of CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. CIG MEDIA GROUP, LP.
-
Committee Memberships
Date Role Committee Institution Country 2020 - 2022 Chair Biomedicine Discovery Research Institute Early Career Research Committee- Workshop Subcommittee Monash University Australia 2016 - ongoing Member Australian Society for Medical Research- State Committee - -
Connect With Me
External Profiles
